Ogochukwu Izuegbuna, Israel Kolawole, Saliu Oguntola, Tiwalade Woods-Ali, Oyewale Saburi, Chijioke Chijindu Adindu, Samuel Olatoke, Olawale Adebayo Olakulehin
{"title":"尼日利亚癌症患者中与癌症相关的神经性疼痛的患病率和相关因素-一项单中心横断面研究","authors":"Ogochukwu Izuegbuna, Israel Kolawole, Saliu Oguntola, Tiwalade Woods-Ali, Oyewale Saburi, Chijioke Chijindu Adindu, Samuel Olatoke, Olawale Adebayo Olakulehin","doi":"10.1080/17581869.2025.2494978","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Neuropathic pain is a major challenge in supportive care management among cancer patients. This study aims to evaluate neuropathic pain in Nigerian cancer patients.</p><p><strong>Methods: </strong>This is a cross-sectional study with 126 cancer patients recruited from the University of Ilorin Teaching Hospital and are 18 years and above. Medical records were collected from their medical files and the patients. The painDETECT questionnaire (PDQ) and the numeric rating scale (NRS) were used to determine the level and form pain.</p><p><strong>Results: </strong>Neuropathic pain in the target populace of cancer patients was 23% in prevalence. The mean age of the cancer patients in the study was 53 years; 69.8% were females. A considerable association was seen between neuropathic pain and performance status (<i>p</i> < 0.001), morphine and pregabalin use (<i>p</i> < 0.001). Binary logistic regression analysis, performance status (b = 18.00, <i>p</i> = 0.009) and use of morphine (b = 11.52, <i>p</i> < 0.001) and pregabalin (b = 18.09, <i>p</i> < 0.001) were significantly associated with neuropathic pain. Performance status, and morphine use (<i>p</i> < 0.001) were associated with pain severity.</p><p><strong>Discussion: </strong>This being the first study in Nigeria, neuropathic pain incidence in Nigerian cancer patients is a work in progress. Performance status and some pain modifiers are predictors of neuropathic pain in Nigerian cancer patients.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"251-258"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence and factors associated with cancer-related neuropathic pain among cancer patients in Nigeria - a single-center cross-sectional study.\",\"authors\":\"Ogochukwu Izuegbuna, Israel Kolawole, Saliu Oguntola, Tiwalade Woods-Ali, Oyewale Saburi, Chijioke Chijindu Adindu, Samuel Olatoke, Olawale Adebayo Olakulehin\",\"doi\":\"10.1080/17581869.2025.2494978\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Neuropathic pain is a major challenge in supportive care management among cancer patients. This study aims to evaluate neuropathic pain in Nigerian cancer patients.</p><p><strong>Methods: </strong>This is a cross-sectional study with 126 cancer patients recruited from the University of Ilorin Teaching Hospital and are 18 years and above. Medical records were collected from their medical files and the patients. The painDETECT questionnaire (PDQ) and the numeric rating scale (NRS) were used to determine the level and form pain.</p><p><strong>Results: </strong>Neuropathic pain in the target populace of cancer patients was 23% in prevalence. The mean age of the cancer patients in the study was 53 years; 69.8% were females. A considerable association was seen between neuropathic pain and performance status (<i>p</i> < 0.001), morphine and pregabalin use (<i>p</i> < 0.001). Binary logistic regression analysis, performance status (b = 18.00, <i>p</i> = 0.009) and use of morphine (b = 11.52, <i>p</i> < 0.001) and pregabalin (b = 18.09, <i>p</i> < 0.001) were significantly associated with neuropathic pain. Performance status, and morphine use (<i>p</i> < 0.001) were associated with pain severity.</p><p><strong>Discussion: </strong>This being the first study in Nigeria, neuropathic pain incidence in Nigerian cancer patients is a work in progress. Performance status and some pain modifiers are predictors of neuropathic pain in Nigerian cancer patients.</p>\",\"PeriodicalId\":20000,\"journal\":{\"name\":\"Pain management\",\"volume\":\" \",\"pages\":\"251-258\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pain management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17581869.2025.2494978\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17581869.2025.2494978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:神经性疼痛是癌症患者支持治疗管理的主要挑战。本研究旨在评估尼日利亚癌症患者的神经性疼痛。方法:本研究是一项横断面研究,从伊洛林大学教学医院招募了126名年龄在18岁及以上的癌症患者。从他们的医疗档案和患者中收集医疗记录。采用painDETECT问卷(PDQ)和数字评定量表(NRS)确定疼痛的程度和形式。结果:神经性疼痛在癌症患者目标人群中的患病率为23%。研究中癌症患者的平均年龄为53岁;69.8%为女性。神经性疼痛与工作状态(p p = 0.009)和吗啡使用(b = 11.52, p p p p)之间存在相当大的关联。讨论:这是尼日利亚的首次研究,尼日利亚癌症患者的神经性疼痛发生率尚在研究中。运动状态和一些疼痛调节剂是尼日利亚癌症患者神经性疼痛的预测因子。
Prevalence and factors associated with cancer-related neuropathic pain among cancer patients in Nigeria - a single-center cross-sectional study.
Objectives: Neuropathic pain is a major challenge in supportive care management among cancer patients. This study aims to evaluate neuropathic pain in Nigerian cancer patients.
Methods: This is a cross-sectional study with 126 cancer patients recruited from the University of Ilorin Teaching Hospital and are 18 years and above. Medical records were collected from their medical files and the patients. The painDETECT questionnaire (PDQ) and the numeric rating scale (NRS) were used to determine the level and form pain.
Results: Neuropathic pain in the target populace of cancer patients was 23% in prevalence. The mean age of the cancer patients in the study was 53 years; 69.8% were females. A considerable association was seen between neuropathic pain and performance status (p < 0.001), morphine and pregabalin use (p < 0.001). Binary logistic regression analysis, performance status (b = 18.00, p = 0.009) and use of morphine (b = 11.52, p < 0.001) and pregabalin (b = 18.09, p < 0.001) were significantly associated with neuropathic pain. Performance status, and morphine use (p < 0.001) were associated with pain severity.
Discussion: This being the first study in Nigeria, neuropathic pain incidence in Nigerian cancer patients is a work in progress. Performance status and some pain modifiers are predictors of neuropathic pain in Nigerian cancer patients.